Seek Returns

PCVX vs. RGEN: Vaxcyte vs. Repligen Stock Comparison

How do Vaxcyte (PCVX) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Vaxcyte (PCVX) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PCVX is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.

Repligen (RGEN) has more than two decades of public-market history since April 29, 1986, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Company profile comparison for Vaxcyte (PCVX) and Repligen (RGEN)
Profile ItemPCVXRGEN
NameVaxcyte Inc.Repligen Corporation
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization10.11 billion USD11.09 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 12, 2020April 29, 1986
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

PCVX
RGEN
GSPC
Loading price history…
Vaxcyte (PCVX) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Vaxcyte (PCVX) and Repligen (RGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Vaxcyte (PCVX) and Repligen (RGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
Total Return (1Y)59.00%23.28%
Total Return (3Y, Annualized)11.29%6.20%
Total Return (5Y, Annualized)21.60%-8.41%

Risk Profile

Drawdown History

PCVX
RGEN
GSPC
Loading price history…
Vaxcyte (PCVX) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Vaxcyte (PCVX) and Repligen (RGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
Volatility (1Y, Annualized)56.01%46.73%
Beta (5Y)1.261.11
Max Drawdown (5Y)-76.22%-64.67%
Avg. Volume (3M)2.12M1.18M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
PCVX and RGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
Sharpe Ratio (1Y)0.980.41
Sortino Ratio (1Y)1.760.60

Profitability

ROE (TTM)

Both Vaxcyte (PCVX) at -42.68% and Repligen (RGEN) at -0.57% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Vaxcyte (PCVX) at 0.00% and Repligen (RGEN) at 6.19% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
ROE (TTM)-42.68%-0.57%
ROA (TTM)-24.98%1.40%
Net Margin (TTM)0.00%-1.47%
Operating Margin (TTM)0.00%6.19%
Gross Margin (TTM)0.00%53.77%

Growth

Revenue Growth

Only one side can be read here: Repligen (RGEN) reports revenue growth of 16.36%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Vaxcyte (PCVX) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
Revenue Growth (YoY)--16.36%
Revenue Growth (3Y CAGR)---2.70%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)---35.73%

Financial Strength

Current Ratio (MRQ)

Both Vaxcyte (PCVX) at 4.56 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Vaxcyte (PCVX) at 0.09 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
Current Ratio (MRQ)4.569.88
Debt / Equity (MRQ)0.090.33
Net Debt / EBITDA---1.19

Dividends

Dividend Yield (TTM)

Neither Vaxcyte (PCVX) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Vaxcyte (PCVX) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither Vaxcyte (PCVX) nor Repligen (RGEN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for Repligen (RGEN), whose P/S ratio of 13.77 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): PCVX does not report P/S ratio, so it has no value marker; RGEN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

On P/B ratio, both Vaxcyte (PCVX) at 3.83 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Vaxcyte (PCVX) vs. Repligen (RGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Vaxcyte (PCVX) and Repligen (RGEN)
MetricPCVXRGEN
P/E Ratio (TTM)----
P/S Ratio (TTM)--13.77
P/B Ratio (MRQ)3.834.70
Free Cash Flow Yield (TTM)-5.24%1.01%